Cleve Clin J Med. 2020 Aug 20. doi: 10.3949/ccjm.87a.ccc059. Online ahead of print.
ABSTRACT
Most antiviral or immunomodulatory therapies investigated for use in patients with COVID-19 have failed to show any mortality benefit. Similar to the previous pandemics caused by respiratory viruses, the role and benefit of corticosteroids has been under debate in COVID-19-related pulmonary disease. In this consult, we discuss the evidence regarding the efficacy of corticosteroid use in hospitalized patients with COVID-19, including data from the first randomized controlled trial on this subject.
PMID:32819962 | DOI:10.3949/ccjm.87a.ccc059